EN 简
EN 简

学术文献

标题

疾病领域

Preliminary Safety and Efficacy of the Combination Therapy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Treating Chronic HBV Infection
Presentation at the 2023 APASL
2023年2月18日

乙型肝炎
Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
Presentation at ID Week 2022
2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
Presentation at ID Week 2022
2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-296, An Extended-Release Injectable Aqueous Suspension Formulation of Brexanolone in Healthy Adult Subjects
Presentation at the International Marcé Society Conference
2022年9月19日

PPD
Amubarvimab/Romlusevimab: First Approval
Drugs
2022年8月23日

COVID-19
Safety and Antiviral Activity of Two Monthly Administration of BRII-835 (VIR-2218), an X-Targeting RNAi Therapeutic, in Chinese Patients with Chronic HBV Infection
Presentation at the 2022 APASL conference
2022年3月31日

乙型肝炎
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
JHEP Reports
2021年9月07日

乙型肝炎
Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
medRxiv
2021年7月23日

COVID-19